Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Shuto

Showing results (71-80 of 182) with videos related to

Pageof 19
Sort By:
Prostaglandins & Other Lipid Mediators|February 18, 2026
Resolvin E1 and Resolvin E2 suppress cyclooxygenase-2 expression through ubiquitin-proteasome-mediated degradation in human macrophage-like U937 cellsAyaka Hamaguchi, Hayato Fukuda, Mizuki Watanabe, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 9, 2023
Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal CortexSatoshi Deyama, Shun Aoki, Rinako Sugie, et al.
Journal of Biotechnology|July 9, 2013
A fluorescence-based method for evaluating inositol 1,4,5-trisphosphate receptor ligands: determination of subtype selectivity and partial agonist effectsAkihiko Tanimura, Tetsuya Mochizuki, Takao Morita, et al.
Chemical & Pharmaceutical Bulletin|July 20, 2002
Conformational analysis of the NMDA receptor antagonist (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) designed by a novel conformational restriction method based on the structural feature of cyclopropane ringSizuka Ono, Kiyoshi Ogawa, Kanako Yamashita, et al.
Bioorganic & Medicinal Chemistry|September 16, 2011
Synthesis of a series of 3,4-methanoarginines as side-chain conformationally restricted analogues of arginineMizuki Watanabe, Kazuya Yamaguchi, Wei Tang, et al.
Behavioural Brain Research|November 21, 2021
The antidepressant-like effect of resolvin E1 in repeated prednisolone-induced depression model miceShun Aoki, Satoshi Deyama, Rinako Sugie, et al.
Chemical & Pharmaceutical Bulletin|August 2, 2016
Development of a Sulfur-Modified Glass-Supported Pd Nanoparticle Catalyst for Suzuki-Miyaura CouplingMincen Xiao, Naoyuki Hoshiya, Katsumasa Fujiki, et al.
Organic Letters|June 8, 2022
Synthesis of γ-Aminobutyric Acid (GABA) Analogues Conformationally Restricted by Bicyclo[3.1.0]hexane/hexene or [4.1.0]Heptane/heptene Backbones as Potent Betaine/GABA Transporter InhibitorsKeisuke Mitsui, Maria E K Lie, Naoki Saito, et al.
ACS Omega|October 18, 2021
Visualized and Quantitative Conformational Analysis of PeptidomimeticsHajime Takashima, Atsushi Yoshimori, Eiji Honda, et al.
Bioorganic & Medicinal Chemistry|April 9, 2002
Synthesis of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) derivatives modified at the carbamoyl moiety as a new class of NMDA receptor antagonistsYuji Kazuta, Ryuichi Tsujita, Kiyoshi Ogawa, et al.
Pageof 19

Showing results (71-80 of 182) with videos related to

Sort By:
Pageof 19
Prostaglandins & Other Lipid Mediators|February 18, 2026
Resolvin E1 and Resolvin E2 suppress cyclooxygenase-2 expression through ubiquitin-proteasome-mediated degradation in human macrophage-like U937 cellsAyaka Hamaguchi, Hayato Fukuda, Mizuki Watanabe, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 9, 2023
Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal CortexSatoshi Deyama, Shun Aoki, Rinako Sugie, et al.
Journal of Biotechnology|July 9, 2013
A fluorescence-based method for evaluating inositol 1,4,5-trisphosphate receptor ligands: determination of subtype selectivity and partial agonist effectsAkihiko Tanimura, Tetsuya Mochizuki, Takao Morita, et al.
Chemical & Pharmaceutical Bulletin|July 20, 2002
Conformational analysis of the NMDA receptor antagonist (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) designed by a novel conformational restriction method based on the structural feature of cyclopropane ringSizuka Ono, Kiyoshi Ogawa, Kanako Yamashita, et al.
Bioorganic & Medicinal Chemistry|September 16, 2011
Synthesis of a series of 3,4-methanoarginines as side-chain conformationally restricted analogues of arginineMizuki Watanabe, Kazuya Yamaguchi, Wei Tang, et al.
Behavioural Brain Research|November 21, 2021
The antidepressant-like effect of resolvin E1 in repeated prednisolone-induced depression model miceShun Aoki, Satoshi Deyama, Rinako Sugie, et al.
Chemical & Pharmaceutical Bulletin|August 2, 2016
Development of a Sulfur-Modified Glass-Supported Pd Nanoparticle Catalyst for Suzuki-Miyaura CouplingMincen Xiao, Naoyuki Hoshiya, Katsumasa Fujiki, et al.
Organic Letters|June 8, 2022
Synthesis of γ-Aminobutyric Acid (GABA) Analogues Conformationally Restricted by Bicyclo[3.1.0]hexane/hexene or [4.1.0]Heptane/heptene Backbones as Potent Betaine/GABA Transporter InhibitorsKeisuke Mitsui, Maria E K Lie, Naoki Saito, et al.
ACS Omega|October 18, 2021
Visualized and Quantitative Conformational Analysis of PeptidomimeticsHajime Takashima, Atsushi Yoshimori, Eiji Honda, et al.
Bioorganic & Medicinal Chemistry|April 9, 2002
Synthesis of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) derivatives modified at the carbamoyl moiety as a new class of NMDA receptor antagonistsYuji Kazuta, Ryuichi Tsujita, Kiyoshi Ogawa, et al.
Pageof 19